|
LMBRD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63347113613099E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.50788279032577E-12 |
| Normal-vs-Stage2 |
1.60052999998994E-05 |
| Normal-vs-Stage3 |
1.44795286871613E-12 |
| Normal-vs-Stage4 |
8.15549960897499E-10 |
| Stage1-vs-Stage2 |
4.430600E-01 |
| Stage1-vs-Stage3 |
2.632400E-01 |
| Stage1-vs-Stage4 |
2.871200E-01 |
| Stage2-vs-Stage3 |
1.350420E-01 |
| Stage2-vs-Stage4 |
1.446370E-01 |
| Stage3-vs-Stage4 |
8.248000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.88098491916389E-15 |
| Normal-vs-AfricanAmerican |
1.190100E-04 |
| Normal-vs-Asian |
1.87299997733703E-09 |
| Caucasian-vs-AfricanAmerican |
4.437000E-01 |
| Caucasian-vs-Asian |
5.237400E-01 |
| AfricanAmerican-vs-Asian |
2.480000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.2757355695785E-12 |
| Normal-vs-Female |
5.16964249186458E-12 |
| Male-vs-Female |
1.421610E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.23859869214516E-11 |
| Normal-vs-Age(41-60Yrs) |
1.20892185151433E-12 |
| Normal-vs-Age(61-80Yrs) |
2.17240003763663E-10 |
| Normal-vs-Age(81-100Yrs) |
1.741750E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.296200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.160800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.413600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.509200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.292800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.298800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.875500E-03 |
| Classical-VS-Follicular |
6.075600E-01 |
| Classical-VS-Other |
5.820500E-02 |
| Classical-VS-Normal |
2.12707629287934E-12 |
| Tall-VS-Follicular |
7.759500E-03 |
| Tall-VS-Other |
2.749800E-01 |
| Tall-VS-Normal |
9.85911352557878E-12 |
| Follicular-VS-Other |
5.618700E-03 |
| Follicular-VS-Normal |
3.46690000041505E-07 |
| Other-VS-Normal |
2.42529999971985E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.10786943455332E-12 |
| Normal-vs-N1 |
1.41269995701521E-09 |
| N0-vs-N1 |
3.701200E-01 |
|
|
